Improvement in Glycemic Response After Bariatric Surgery

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05325736

Enrollment

120

Registered

2022-04-13

Start date

2021-07-01

Completion date

2029-07-01

Last updated

2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery

Brief summary

decipher the role of microbiota in glycemic response change after bariatric surgery

Detailed description

Despite the vast knowledge linking the gut microbiome to metabolism and the glucose response, the relation still remains unclear. hopefully, a deep understanding of the mechanisms underlying metabolic improvement following bariatric surgery will make it possible to identify targets for pharmacological intervention, which will reduce the need for surgery and its risks. Previous studies have characterized the microbiome after bariatric surgery, but most suffer from methodological limitations. The current study has the potential to be innovative and make a significant contribution to understanding the mechanisms involved in early metabolic improvement after bariatric surgery.

Interventions

PROCEDUREsleeve gastrectomy surgery

participants undergoing sleeve gastrectomy surgery

PROCEDUREgastric bypass surgery

participants undergoing gastric bypass surgery

PROCEDUREcontrol

cholecystectomy

PROCEDUREPancreatectomy

Collecting a sample of an unidentified healthy pancreas to extract insulin-secreting beta cells from the sample

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* candidates of bariatric surgery or cholecystectomy * age 18-70 * male/female

Exclusion criteria

* previous bariatric surgery * type 1 diabetes * antibiotic treatment 3 months prior to the study * probiotic treatment 3 months prior to the study * chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders * any pathologic findings during endoscopy * participants who will suffer from a post-operation complication

Design outcomes

Primary

Measure	Time frame	Description
Glycemic response	up to 4 years	The glycemic response will be measured by taking a blood test (glucose) after 12 hours fast and a second blood test (glucose) after an OGTT(oral glucose tolerance test) of 50 g glucose
microbiota composition	up to 4 years	The microbiota composition will be assessed using the stool samples of the participants.

Countries

Israel

Contacts

CONTACTAvner Leshem, MD

avner.leshem@weizmann.ac.il+972547487555

STUDY_DIRECTORAvner Leshem, MD

Weizmann institute

PRINCIPAL_INVESTIGATORDanit Dayan, MD

Souraski medical center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026